Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August 6, 2024
Nyxoah SA (NYXH), a medical technology company focused on innovative solutions for Obstructive Sleep Apnea (OSA), has announced the release of its second quarter and first half 2024 financial results on August 6, 2024, after market close. The company will host a conference call to discuss the financial results on the same day at 10:30pm CET / 4:30pm ET.
Investors and interested parties can access the earnings call webcast through the Investor Relations page of Nyxoah's website or via a provided link. Those planning to ask questions during the call are advised to register separately using a different link. Registration is recommended at least 10 minutes before the call starts to ensure proper connection. An archived version of the webcast will be available for replay shortly after the call concludes.
Nyxoah SA (NYXH), un'azienda di tecnologia medica focalizzata su soluzioni innovative per l'Apnea Ostruttiva del Sonno (OSA), ha annunciato il rilascio dei risultati finanziari del secondo trimestre e del primo semestre 2024 il 6 agosto 2024, dopo la chiusura dei mercati. L'azienda ospiterà una conference call per discutere i risultati finanziari lo stesso giorno alle 22:30 CET / 16:30 ET.
Investitori e parti interessate possono accedere al webcast della call sugli utili tramite la pagina delle Relazioni con gli Investitori del sito web di Nyxoah o tramite un link fornito. Coloro che intendono porre domande durante la call sono invitati a registrarsi separatamente utilizzando un link diverso. La registrazione è consigliata almeno 10 minuti prima dell'inizio della call per garantire una connessione corretta. Una versione archiviata del webcast sarà disponibile per la riproduzione subito dopo la conclusione della call.
Nyxoah SA (NYXH), una empresa de tecnología médica centrada en soluciones innovadoras para la Apnea Obstructiva del Sueño (OSA), ha anunciado la publicación de sus resultados financieros del segundo trimestre y la primera mitad de 2024 el 6 de agosto de 2024, después del cierre del mercado. La empresa llevará a cabo una conferencia telefónica para discutir los resultados financieros el mismo día a las 10:30 pm CET / 4:30 pm ET.
Los inversionistas y partes interesadas pueden acceder al webcast de la llamada de ganancias a través de la página de Relaciones con Inversionistas del sitio web de Nyxoah o mediante un enlace proporcionado. Aquellos que planean hacer preguntas durante la llamada se aconseja registrarse por separado utilizando un enlace diferente. Se recomienda registrarse al menos 10 minutos antes de que comience la llamada para asegurar una conexión adecuada. Una versión archivada del webcast estará disponible para su reproducción poco después de que termine la llamada.
Nyxoah SA (NYXH)는 폐쇄성 수면 무호흡증 (OSA)에 대한 혁신적인 솔루션에 중점을 둔 의료기술 회사로, 2024년 8월 6일에 시장 폐장 이후 두 번째 분기와 상반기 재무 결과를 발표한다고 발표했습니다. 회사는 같은 날 오후 10:30 CET / 오후 4:30 ET에 재무 결과에 대해 논의하는 컨퍼런스 콜을 개최할 예정입니다.
투자자 및 관심 있는 관련자는 Nyxoah의 웹사이트 투자자 관계 페이지 또는 제공된 링크를 통해 수익 콜 웹캐스트에 접근할 수 있습니다. 콜 중 질문할 계획이 있는 사람은 별도의 링크를 사용하여 별도로 등록할 것을 권장합니다. 연결을 보장하기 위해 콜 시작 최소 10분 전에 등록하는 것이 좋습니다. 콜 종료 직후 재생을 위해 웹캐스트의 아카이브 버전을 이용할 수 있습니다.
Nyxoah SA (NYXH), une entreprise de technologie médicale axée sur des solutions innovantes pour l'apnée obstructive du sommeil (AOS), a annoncé la publication de ses résultats financiers du deuxième trimestre et de la première moitié de 2024 le 6 août 2024, après la fermeture du marché. L'entreprise organisera une conférence téléphonique pour discuter des résultats financiers le même jour à 22h30 CET / 16h30 ET.
Les investisseurs et les parties intéressées peuvent accéder au webcast de l'appel de résultats via la page des Relations Investisseurs du site de Nyxoah ou via un lien fourni. Ceux qui prévoient de poser des questions lors de l'appel sont invités à s'inscrire séparément en utilisant un lien différent. Il est recommandé de s'inscrire au moins 10 minutes avant le début de l'appel pour garantir une bonne connexion. Une version archivée du webcast sera disponible pour rediffusion peu après la conclusion de l'appel.
Nyxoah SA (NYXH), ein Unternehmen für Medizintechnologie, das sich auf innovative Lösungen zur Behandlung der obstruktiven Schlafapnoe (OSA) spezialisiert hat, hat die Veröffentlichung der finanziellen Ergebnisse für das zweite Quartal und die erste Hälfte des Jahres 2024 für den 6. August 2024 nach Marktschluss angekündigt. Das Unternehmen wird am selben Tag um 22:30 Uhr CET / 16:30 Uhr ET eine Telefonkonferenz abhalten, um die finanziellen Ergebnisse zu diskutieren.
Investoren und interessierte Parteien können auf das Webcast der Gewinnanruf über die Investor Relations-Seite der Nyxoah-Website oder über einen bereitgestellten Link zugreifen. Personen, die während des Anrufs Fragen stellen möchten, wird geraten, sich separat über einen anderen Link zu registrieren. Eine Registrierung wird empfohlen, mindestens 10 Minuten vor Beginn des Anrufs, um eine angemessene Verbindung sicherzustellen. Eine archivierte Version des Webcasts wird kurz nach Abschluss des Anrufs zur Verfügung stehen.
- None.
- None.
Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August 6, 2024
Mont-Saint-Guibert, Belgium – July 29, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the second quarter and first half 2024 on Tuesday, August 6, 2024, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.
A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q2 2024 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.
If you plan to ask a question, please use the following link: Nyxoah’s Q2 2024 earnings call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.
The archived webcast will be available for replay shortly after the close of the call.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.
Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
IR@nyxoah.com
For Media
Belgium/France
Backstage Communication – Gunther De Backer
gunther@backstagecom.be
International/Germany
MC Services – Anne Hennecke
anne.hennecke@mc-services.eu
Attachment
FAQ
When will Nyxoah (NYXH) release its Q2 and H1 2024 financial results?
What time is Nyxoah's (NYXH) Q2 2024 earnings call scheduled for?
How can investors access Nyxoah's (NYXH) Q2 2024 earnings call?
Will there be a replay available for Nyxoah's (NYXH) Q2 2024 earnings call?
